Pharmaceutical composition for treatment of dry eye syndrome
First Claim
Patent Images
1. A pharmaceutical composition comprising:
- (a) a therapeutically effective amount of an active ingredient selected from the group of macrolide immunosuppressants useful in the prevention or therapy of keratoconjunctivitis sicca or a symptom associated therewith, and(b) liquid vehicle comprising a semifluorinated alkane, wherein the pharmaceutical composition is formulated as a clear solution.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
-
Citations
13 Claims
-
1. A pharmaceutical composition comprising:
-
(a) a therapeutically effective amount of an active ingredient selected from the group of macrolide immunosuppressants useful in the prevention or therapy of keratoconjunctivitis sicca or a symptom associated therewith, and (b) liquid vehicle comprising a semifluorinated alkane, wherein the pharmaceutical composition is formulated as a clear solution. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 12, 13)
-
-
10. A pharmaceutical composition comprising:
-
(a) a therapeutically effective amount of an active ingredient selected from the group of macrolide immunosuppressants useful in the prevention or therapy of keratoconjunctivitis sicca or a symptom associated therewith; (b) a liquid vehicle comprising a semifluorinated alkane; and (C) ethanol. - View Dependent Claims (11)
-
Specification